Document Detail


Angiotensin receptor antagonism and angiotensin converting enzyme inhibition improve diastolic dysfunction and Ca(2+)-ATPase expression in the sarcoplasmic reticulum in hypertensive cardiomyopathy.
MedLine Citation:
PMID:  9321748     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Hypertensive cardiomyopathy is a major risk factor for the development of chronic heart failure. OBJECTIVE: To investigate whether treatment with an angiotensin converting enzyme inhibitor (ACEI) or with an angiotensin type 1 receptor antagonist (AT1-RA) is sufficient to prevent the development of hypertensive cardiomyopathy and cardiac contractile dysfunction. Special emphasis was placed on the effects of both treatments on sarcoplasmic reticulum Ca(2+)-ATPase (SERCA 2a) gene expression as a major cause of impaired diastolic cardiac relaxation. METHODS AND RESULTS: Eight-week-old rats harboring the mouse renin 2d gene [TG(mREN2)27] were treated for 8 weeks with 100 mg/kg captopril (Cap) in their food and 100 mg/kg of the AT1-RA Bay 10-6734 (Bay) in their food. Untreated TG(mREN2)27 and Sprague-Dawley rats (SDR) were used as controls. Both treatment regimens normalized the left ventricular weight, which was increased significantly (P < 0.001) in TG(mREN2)27. Both treatments normalized the left ventricular end-systolic and end-diastolic pressures, which were significantly (P < 0.001) higher in TG(mREN2)27 than they were in SDR, and they improved the velocity of the decrease in pressure [P < 0.05, Bay and Cap versus TG(mREN2)27]. Decreased left ventricular SERCA 2a mRNA and protein levels and increased atrial natriuretic peptide messenger RNA levels were normalized by Bay and Cap treatments (P < 0.05, Bay and Cap versus TG(mREN2)27, by Northern and Western blotting). According to radioimmunoassay and an enzyme assay, respectively, Bay, but not Cap, increased plasma angiotensin I concentrations and the renin activity above normal levels (P < 0.05), whereas myocardial angiotensin II concentrations (determined by radioimmunoassay), which were significantly (P < 0.05) increased in TG(mREN2)27, were normalized equally by Bay and Cap. CONCLUSIONS: In renin-induced hypertensive cardiomyopathy, left ventricular diastolic dysfunction occurs at the stage of compensated myocardial hypertrophy. The decreased left ventricular relaxation velocity might be due to reduced SERCA 2a gene expression. In this model of hypertensive cardiomyopathy, AT1-RA and ACEI treatments are similarly effective at reducing the arterial pressure, preventing myocardial hypertrophy and diastolic contractile dysfunction. Normalization of SERCA 2a gene expression, either by AT1-RA or by ACEI treatment, might contribute to the improvement in diastolic function.
Authors:
M Flesch; F Schiffer; O Zolk; Y Pinto; J P Stasch; A Knorr; S Ettelbrück; M Böhm
Related Documents :
17488768 - Renin: friend or foe?
1849368 - Cardiovascular and renin responses to desmopressin in humans: role of prostacyclin and ...
6206588 - Changes in the kallikrein kinin system during acute pancreatitis in man.
732728 - Emergency treatment of severe hypertension with intravenous labetalol.
23757508 - Hypercapnia counteracts captopril-induced depression of gastric mucosal oxygenation.
22940068 - Effect of dexmedetomidine vs. acepromazine-methadone premedication on limb to lung circ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of hypertension     Volume:  15     ISSN:  0263-6352     ISO Abbreviation:  J. Hypertens.     Publication Date:  1997 Sep 
Date Detail:
Created Date:  1998-01-13     Completed Date:  1998-01-13     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8306882     Medline TA:  J Hypertens     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  1001-9     Citation Subset:  IM    
Affiliation:
Klinik III für Innere Medizin der Universität zu Köln, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensin I / blood
Angiotensin II / analysis
Angiotensin-Converting Enzyme Inhibitors / pharmacology*
Animals
Atrial Natriuretic Factor / metabolism
Blotting, Northern
Blotting, Western
Calcium-Transporting ATPases / metabolism*
Captopril / pharmacology
Cardiomyopathy, Hypertrophic / drug therapy,  etiology,  metabolism,  physiopathology*
Diastole / drug effects*
Dihydropyridines / pharmacology
Disease Models, Animal
Heart Ventricles / metabolism
Hemodynamics / drug effects
Hypertension / complications,  drug therapy,  metabolism,  physiopathology*
Mice
Mice, Transgenic
Myocardium / chemistry,  metabolism
RNA, Messenger / analysis
Rats
Rats, Sprague-Dawley
Receptors, Angiotensin / antagonists & inhibitors*
Renin / blood,  genetics
Sarcoplasmic Reticulum / drug effects,  metabolism*
Tetrazoles / pharmacology
Chemical
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Dihydropyridines; 0/RNA, Messenger; 0/Receptors, Angiotensin; 0/Tetrazoles; 11128-99-7/Angiotensin II; 156001-18-2/embusartan; 62571-86-2/Captopril; 85637-73-6/Atrial Natriuretic Factor; 9041-90-1/Angiotensin I; EC 3.4.23.15/Renin; EC 3.6.1.8/Calcium-Transporting ATPases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Influence of the angiotensin converting enzyme I/D gene polymorphisms on left ventricular diastolic ...
Next Document:  Relation of left ventricular longitudinal and circumferential shortening to ejection fraction in the...